Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Fair Value (Tables)

Fair Value (Tables)

6 Months Ended

Jun. 30, 2012

Schedule of financial assets measured at fair value on a recurring basis

	Assets at Fair Value as of June 30, 2012
	Level 1		Level 2		Level 3		Total
Money market funds	$	15,893	$	—	$	—	$	15,893
Government-sponsored enterprise securities	—		80,085		—		80,085
Corporate bonds and commercial paper	—		105,352		—		105,352

Total	$	15,893	$	185,437	$	—	$	201,330

	Assets at Fair Value as of December 31, 2011
	Level 1		Level 2		Level 3		Total
Money market funds	$	11,947	$	—	$	—	$	11,947
U. S. treasury bills	—		3,002		—		3,002
Government-sponsored enterprise securities	—		144,599		—		144,599
Corporate bonds and commercial paper	—		87,406		—		87,406

Total	$	11,947	$	235,007	$	—	$	246,954

- Definition

Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).

+ References + Details